Showing posts with label Medtronic. Show all posts
Showing posts with label Medtronic. Show all posts
Wednesday, March 31, 2010
Eighth Circuit Sets New Date for Oral Argument on Appeal of Federal Case Dismissal
The Eighth Circuit Court of Appeals has notified the parties of a new date for oral argument in plaintiffs’ appeal of the dismissal of complaints against Medtronic for its faulty heart devices. The appeal will now be heard on April 12, 2010, in St. Louis, Missouri. Oral argument had originally been set for January 2010. The state court appeal date has not yet been scheduled. The parties are still briefing their sides of the case.
Monday, August 3, 2009
Medical Device Safety Act Hearing before the Senate HELP Committee
Tomorrow we will hear from the following people regarding the Medical Device Safety Act, at at hearing before the Senate HELP Committee entitled, "Protecting Patients from Defective Medical Devices,":
- William H. Maisel, MD, MPH, Director, Medical Device Safety Institute,Beth Israel, Deaconess Medical Center, Harvard Medical School, Boston, MA
- Professor Thomas O. McGarity, Joe R. and Teresa Lozano Long Endowed Chair in Administrative Law, University of Texas School of Law, Austin, TX
- Michael Mulvihill, Patient, Bettendorf, IA
- Peter Barton Hutt, Esq., Senior Counsel in Food and Drug Law, Covington & Burling, Washington, DC
- Michael Roman, Patient, Kirkwood, MO
For those who are not aware, the Medical Device Safety Act of 2009 will restore patients rights to sue a manufacturer of a faulty / defective medical device when they have been injured. The current state of the law provides a 'Get out of jail for free' card to device manufacturers so long as their device is FDA-approved. Without this law, patients will have no recourse for their injuries, and the cost will be shifted to taxpayers for medical bills, among other things. Medical device manufacturers should be accountable for their products, and allowing lawsuits will ensure that device manufacturers put the safest products on the market. We've learned from many other product liability lawsuits that large companies many time put profits over people. A Lawsuit is just one of the many mechanisms that will provide adequate checks and balances.
The hearing will begin at 2:30 p.m. on August 4, 2009 in SD-430.
- William H. Maisel, MD, MPH, Director, Medical Device Safety Institute,Beth Israel, Deaconess Medical Center, Harvard Medical School, Boston, MA
- Professor Thomas O. McGarity, Joe R. and Teresa Lozano Long Endowed Chair in Administrative Law, University of Texas School of Law, Austin, TX
- Michael Mulvihill, Patient, Bettendorf, IA
- Peter Barton Hutt, Esq., Senior Counsel in Food and Drug Law, Covington & Burling, Washington, DC
- Michael Roman, Patient, Kirkwood, MO
For those who are not aware, the Medical Device Safety Act of 2009 will restore patients rights to sue a manufacturer of a faulty / defective medical device when they have been injured. The current state of the law provides a 'Get out of jail for free' card to device manufacturers so long as their device is FDA-approved. Without this law, patients will have no recourse for their injuries, and the cost will be shifted to taxpayers for medical bills, among other things. Medical device manufacturers should be accountable for their products, and allowing lawsuits will ensure that device manufacturers put the safest products on the market. We've learned from many other product liability lawsuits that large companies many time put profits over people. A Lawsuit is just one of the many mechanisms that will provide adequate checks and balances.
The hearing will begin at 2:30 p.m. on August 4, 2009 in SD-430.
Labels:
HELP,
hutt,
kirkwood,
Maisel,
mcgarity,
MDSA,
Medical Device Safety Act 2009,
medical devices,
Medtronic,
mulvilhill,
Senate
Thursday, June 18, 2009
Medtronic Paid $800,000 to a Surgeon Accused of Falsifying Study
Meditronic, the well-known medical device maker, is in the headlines once again. This time, Medtronic says it paid approximately $800,000 over the past 3 years to a former Army surgeon accused of fabricating a study that reported positive results for one of the company's key spine products. This type of pay isn't too shabby for writing falsities!
Some of the consulting payments were made when the surgeon, Timothy R. Kuklo, was shopping his favorable study of Medtronic's Infuse bone-graft product to medical journals. The paper, ultimately published last August in the Journal of Bone and Joint Surgery, reported advantages in healing the legs of injured soldiers when Infuse was used.
The Army has said that the study is based on "falsified information" and that Dr. Kuklo forged the signatures of purported co-authors. Dr. Kuklo listed his affiliation with Walter Reed Army Medical Center in the journal. He left the Army hospital in August 2006 and joined the faculty of Washington University in St. Louis.
Medtronic disclosed the payments to The Wall Street Journal Wednesday. Of course, Medtronic says the payments were compensation for Dr. Kuklo's work developing products for the company, training doctors and speaking at company events and that they weren't connected to the study or journal article in any way.
Bone and Joint Surgery withdrew the paper after the Army contacted it about the fraud allegations. Dr. Kuklo, who has taken a leave from the university, hasn't commented publicly on the matter and didn't return a message left at his home Wednesday. The university declined to say whether it was investigating Dr. Kuklo.
In 2007, Dr. Kuklo offered the study to at least two medical journals, according to the publications. Medtronic says it paid him $356,242 that year for consulting, speaking, travel and training services. In 2008, the year the study was published, Medtronic says it paid Dr. Kuklo $249,772. While Medtronic says that its consulting arrangements with surgeons are critical to the development of new products, its payments to surgeons who use its spine products are under investigation by the Justice Department following accusations by several former employees that the doctors were being induced to use the products -- allegations the company denies.
Medtronic last year provided Congress with a list of 22 consultants who worked specifically on Infuse-related matters. The payments to those doctors ranged from $100 a year to $67,600. Surgeons with more general consulting arrangements, such as Dr. Kuklo, can earn a lot more. Jeffrey Wang, chief of spine surgery at the University of California, Los Angeles, reported receiving $186,700 in product development, royalty and teaching payments from Medtronic from 2004 through 2007.
Medtronic placed its consulting relationship with Dr. Kuklo on "inactive status" in May, when the Army disclosed it had found problems with the study. In the first few months of 2009, it paid him $132,453. Medtronic also says it paid Dr. Kuklo smaller amounts, including $42,627 in 2006, and picked up his expenses while he worked for the Army. The latter payments, which total $42,295 from 2001 through 2005, were primarily tied to travel to medical conferences and speeches at Medtronic events.
Some of the consulting payments were made when the surgeon, Timothy R. Kuklo, was shopping his favorable study of Medtronic's Infuse bone-graft product to medical journals. The paper, ultimately published last August in the Journal of Bone and Joint Surgery, reported advantages in healing the legs of injured soldiers when Infuse was used.
The Army has said that the study is based on "falsified information" and that Dr. Kuklo forged the signatures of purported co-authors. Dr. Kuklo listed his affiliation with Walter Reed Army Medical Center in the journal. He left the Army hospital in August 2006 and joined the faculty of Washington University in St. Louis.
Medtronic disclosed the payments to The Wall Street Journal Wednesday. Of course, Medtronic says the payments were compensation for Dr. Kuklo's work developing products for the company, training doctors and speaking at company events and that they weren't connected to the study or journal article in any way.
Bone and Joint Surgery withdrew the paper after the Army contacted it about the fraud allegations. Dr. Kuklo, who has taken a leave from the university, hasn't commented publicly on the matter and didn't return a message left at his home Wednesday. The university declined to say whether it was investigating Dr. Kuklo.
In 2007, Dr. Kuklo offered the study to at least two medical journals, according to the publications. Medtronic says it paid him $356,242 that year for consulting, speaking, travel and training services. In 2008, the year the study was published, Medtronic says it paid Dr. Kuklo $249,772. While Medtronic says that its consulting arrangements with surgeons are critical to the development of new products, its payments to surgeons who use its spine products are under investigation by the Justice Department following accusations by several former employees that the doctors were being induced to use the products -- allegations the company denies.
Medtronic last year provided Congress with a list of 22 consultants who worked specifically on Infuse-related matters. The payments to those doctors ranged from $100 a year to $67,600. Surgeons with more general consulting arrangements, such as Dr. Kuklo, can earn a lot more. Jeffrey Wang, chief of spine surgery at the University of California, Los Angeles, reported receiving $186,700 in product development, royalty and teaching payments from Medtronic from 2004 through 2007.
Medtronic placed its consulting relationship with Dr. Kuklo on "inactive status" in May, when the Army disclosed it had found problems with the study. In the first few months of 2009, it paid him $132,453. Medtronic also says it paid Dr. Kuklo smaller amounts, including $42,627 in 2006, and picked up his expenses while he worked for the Army. The latter payments, which total $42,295 from 2001 through 2005, were primarily tied to travel to medical conferences and speeches at Medtronic events.
Wednesday, May 13, 2009
Hearing on the Medical Device Safety Act of 2009
Yesterday, my client Bridget Robb testified before the Health Subcommittee of the House Energy and Commerce Committee at a Hearing, Chaired by Congressman Frank Pallone, on the Medical Device Safety Act of 2009. Also in attendance were witnesses:
· David Vladeck, J.D., Professor of Law, Georgetown University Law Center;
· William H. Maisel, M.D., M.P.H., Director, Medical Device Safety Institute,
Department of Medicine, Beth Israel Deaconess Medical Center, Boston;
· Gregory Curfman, M.D., Editor, New England Journal of Medicine;
· Richard Cooper, Partner, Williams & Connolly LLP; and
· Michael Kinsley, Seattle, Washington
Ms. Robb’s testimony detailed the events of her tragic experience of being shocked by a defective medical device 31 times in front of her then five-year-old daughter. Since the event, Ms. Robb’s health has significantly declined and, she and her daughter suffer extreme anxiety related to the events of that day.
Professor Vladeck articulately summarized the current state of the law, its development over the years, and the Congressional intent behind the Medical Device Act – that preemption of state tort law claims was never meant to occur.
Dr. Maisel, who works with the FDA on a number of projects, supports the act and believes that it will assist in the development of safer products. Dr. Maisel testified that the FDA does not have the resources to be the sole gatekeeper of medical device safety. Dr. Curfman of the New England Journal of Medicine expressed the view that without litigation, the dangers of many drugs would never have been brought to light but for litigation and that he supports the act. Mr. Cooper and Mr. Kinsley too positions in favor of the device companies. Mr. Cooper frequently testifies in favor of device manufacturers. Mr. Cooper works for a firm that represents big business and was former counsel for the FDA. Mr. Kinsley, a political journalist who suffers from Parkinson’s and has a device implanted to relieve his symptoms, testified against litigation. Mr. Kinsley has taken an anti-litigation position for years being in the journalism industry. Mr. Kinsley did state that if a company knowingly withholds information from the FDA, they should be held accountable. He offered no opinion on whether the Seventh Amendment (the right to a jury trial) should be protected. His testimony turned into more of a sideshow at the hearing.
The recent decision rendered in Riegel v. Medtronic, gives medical device manufacturers complete immunity when it knowingly places and/or keeps on the market dangerous products. According to the current state of the law, so long as a device complies with FDA standards (even after significant adverse events have been reported) a company cannot be held accountable when their product fails and injures someone. Companies argue that innovation will be stifled; however, only for a short period of time has preemption been applied in medical device cases and for the time it was not applied, innovation was in no way protected.
Currently, consumers of medical devices are not protected when things go wrong and there is no accountability for manufacturers or incentive for manufacturers to make their products safer. Manufacturers keep faulty products on hospital shelves to save costs at the expense of peoples’ lives. Why should drug companies be held accountable and device companies not?
The companies unsuccessfully argue that this is an insurance issue – it’s not. Exorbitant medical bills are only one part of the damages this patients have. In cases like Ms. Robb’s, their lives are forever changed, with increased surgeries, medications and loss of ability to do things in live they were once able to do.
Please reach out to your Congressmen and Congresswomen and express your support for the passing of this law. You might be surprised that many of your representatives support big business over your constitutional right to a trial by jury and patient safety.
· David Vladeck, J.D., Professor of Law, Georgetown University Law Center;
· William H. Maisel, M.D., M.P.H., Director, Medical Device Safety Institute,
Department of Medicine, Beth Israel Deaconess Medical Center, Boston;
· Gregory Curfman, M.D., Editor, New England Journal of Medicine;
· Richard Cooper, Partner, Williams & Connolly LLP; and
· Michael Kinsley, Seattle, Washington
Ms. Robb’s testimony detailed the events of her tragic experience of being shocked by a defective medical device 31 times in front of her then five-year-old daughter. Since the event, Ms. Robb’s health has significantly declined and, she and her daughter suffer extreme anxiety related to the events of that day.
Professor Vladeck articulately summarized the current state of the law, its development over the years, and the Congressional intent behind the Medical Device Act – that preemption of state tort law claims was never meant to occur.
Dr. Maisel, who works with the FDA on a number of projects, supports the act and believes that it will assist in the development of safer products. Dr. Maisel testified that the FDA does not have the resources to be the sole gatekeeper of medical device safety. Dr. Curfman of the New England Journal of Medicine expressed the view that without litigation, the dangers of many drugs would never have been brought to light but for litigation and that he supports the act. Mr. Cooper and Mr. Kinsley too positions in favor of the device companies. Mr. Cooper frequently testifies in favor of device manufacturers. Mr. Cooper works for a firm that represents big business and was former counsel for the FDA. Mr. Kinsley, a political journalist who suffers from Parkinson’s and has a device implanted to relieve his symptoms, testified against litigation. Mr. Kinsley has taken an anti-litigation position for years being in the journalism industry. Mr. Kinsley did state that if a company knowingly withholds information from the FDA, they should be held accountable. He offered no opinion on whether the Seventh Amendment (the right to a jury trial) should be protected. His testimony turned into more of a sideshow at the hearing.
The recent decision rendered in Riegel v. Medtronic, gives medical device manufacturers complete immunity when it knowingly places and/or keeps on the market dangerous products. According to the current state of the law, so long as a device complies with FDA standards (even after significant adverse events have been reported) a company cannot be held accountable when their product fails and injures someone. Companies argue that innovation will be stifled; however, only for a short period of time has preemption been applied in medical device cases and for the time it was not applied, innovation was in no way protected.
Currently, consumers of medical devices are not protected when things go wrong and there is no accountability for manufacturers or incentive for manufacturers to make their products safer. Manufacturers keep faulty products on hospital shelves to save costs at the expense of peoples’ lives. Why should drug companies be held accountable and device companies not?
The companies unsuccessfully argue that this is an insurance issue – it’s not. Exorbitant medical bills are only one part of the damages this patients have. In cases like Ms. Robb’s, their lives are forever changed, with increased surgeries, medications and loss of ability to do things in live they were once able to do.
Please reach out to your Congressmen and Congresswomen and express your support for the passing of this law. You might be surprised that many of your representatives support big business over your constitutional right to a trial by jury and patient safety.
Monday, June 30, 2008
Critics blast feds' legal shields for manufacturers
On June 29, 2008, the Chicago Tribune published an article recapping Bridget Robb's horrific tale of being shocked 31 times in 13 minutes due to a faulty, Medtronic Sprint Fidelis Lead. The article is one of many discussing how injured people, like Ms. Robb, are many times are precluded from recovering for their injuries due to a legal doctrine called "preemption." In effect, injured individuals are precluded from recovering against a company for defects in a product's design and labeling.
Proponents of preemption argue that manufacturers are not insurers and the FDA always has the option of holding a product from the market. During the June 11, 2008 Senate Judiciary Committee hearing at which Ms. Robb testified, Senator Specter called the FDA a joke and said that it is ludicrous to have preemption by an agency that is dysfunctional.
Before the hearing abruptly came to a halt because of a 2-hour rule invoked by a certain Republican Senator, Senator Whitehouse discussed "Regulatory Capture" -- which is when an agency that purports to be a public agency is taken over by the groups it was meant to regulate. Senator Whitehouse believes that the FDA falls within this definition.
Proponents of preemption argue that manufacturers are not insurers and the FDA always has the option of holding a product from the market. During the June 11, 2008 Senate Judiciary Committee hearing at which Ms. Robb testified, Senator Specter called the FDA a joke and said that it is ludicrous to have preemption by an agency that is dysfunctional.
Before the hearing abruptly came to a halt because of a 2-hour rule invoked by a certain Republican Senator, Senator Whitehouse discussed "Regulatory Capture" -- which is when an agency that purports to be a public agency is taken over by the groups it was meant to regulate. Senator Whitehouse believes that the FDA falls within this definition.
Tuesday, June 17, 2008
Minnesota News Channel Airs Bridget Robb's Story
In Minnesota, where Medtronic is located, listeners heard the horrific events of Bridget Robb retold before the Senate Judiciary Committee. I can tell you firsthand that Ms. Robb is one of the bravest people I know. Invited to testify before the Senate Judiciary Committee by Senator Leahy, her main goal is to help others and to make sure that the terrible events of the morning of December 31, do not happen to others. During her testimony, Ms. Robb recounted the terror she experienced after being shocked 31 times due to a fractured Sprint Fidelis lead manufactured by Medtronic.
Ms. Robb's story is just one of many stories told where individuals have been severely harmed by dangerous products placed into the stream of commerce by big businesses that are more focused on profits than safety.
If you click on the title above, you will view a clip of Bridget testifying on June 11. We hope to continue this fight in an effort to make serious change. The law, as it stands, is not consumer friendly and flies in the face of people's fundamental rights to have their case heard in court.
Ms. Robb's story is just one of many stories told where individuals have been severely harmed by dangerous products placed into the stream of commerce by big businesses that are more focused on profits than safety.
If you click on the title above, you will view a clip of Bridget testifying on June 11. We hope to continue this fight in an effort to make serious change. The law, as it stands, is not consumer friendly and flies in the face of people's fundamental rights to have their case heard in court.
Labels:
Bridget Robb,
defibrillator,
Medtronic,
Minnesota,
pacemaker,
Sprint Fidelis lead
Monday, June 16, 2008
BRIDGET ROBB TESTIFIES BEFORE THE SENATE JUDICIARY COMMITTEE ABOUT INJURIES FROM DEFECTIVE MEDTRONIC SPRINT FIDELIS LEAD
On June 11, 2008, I had the pleasure of accompanying Bridget Robb, one of my clients, to Washington, D.C. to testify before the Senate Judiciary Committee, at a hearing entitled “Short-change for Consumers and Short-Shrift for Congress? The Supreme Court’s Treatment of Laws that Protect Americans’ Health, Safety, Jobs and Retirement.” Senator Patrick Leahy (D, Vt.) presided over the hearing. Witness testimony and the live hearing can be viewed at http://judiciary.senate.gov/hearing.cfm?id=3404
Ms. Robb courageously spoke about her harrowing experience with a Medtronic Sprint Fidelis lead in late 2007. Ms. Robb was shocked 31 times due to the defective cardiac lead, which had been recalled two months before her tragic incident. She never received notice of the recall. She described each shock as “if a cannon was being repeatedly shot at [her] chest at close range.” The event was made all the more terrible because our client’s telephone call to 911 was captured on tape, and the pain and agony of the numerous shocks is evident throughout the 7-minute call, which took place in the presence of her young child. Her experience was featured in a Good Morning America segment that ran on Wednesday morning before the hearing, which can also be viewed on the web at http://abcnews.go.com/GMA/OnCall/story?id=5044693&page=1
The hearing focused on how several recent decisions by the U.S. Supreme Court affected consumers’ health and safety, including preemption and ERISA.
Senator Leahy stated that he “called this hearing today to shine a light on how the Supreme Court’s decisions affect Americans’ everyday lives. Often, the Court’s rulings come into focus when they involve divisive cultural issues. Lately, however, many Court observers have noticed that business interests have been the big winners, over workers and consumers. In this worsening economy, mothers and fathers are struggling with health care coverage, the uncertainty of retirement, credit card payments and mortgages. Congress has passed laws to protect Americans in these areas, but in many cases, the Supreme Court has ignored the intent of Congress in passing these measures, oftentimes turning these laws on their heads, and making them protections for big business rather than for ordinary citizens.” During the hearing, Sen. Arlen Specter (R., Pa.) also spoke out forcefully on the failings of the FDA, calling the FDA "a joke."
Also testifying was Maureen Kurtek, a Harrisburg, Pennsylvania, resident, who offered personal testimony about how a recent ruling by the Supreme Court relating to ERISA preemption limited her right as a consumer to seek recovery for harmful practices by an HMO. Other witnesses include Andy Anderson, a lawyer with the law firm of Morgan, Lewis & Bockius LLP; Thomas O. McGarity, a law professor at the University of Texas School of Law; Richard M. Cooper, a partner with the law firm of Williams & Connolly LLP; and Robert Lawless, a law professor at the University of Illinois College of Law.
This hearing helped shed light on the profound effect that the failures of the Food & Drug Administration have on consumers, like Ms. Robb.
I am happy to answer any questions regarding the hearing or the recalled Medtronic Sprint Fidelis lead. Please contact me at (215) 790-7379 with any questions or to discuss your potential case. It is important that the horrible tragedy Ms. Robb experienced does not happen to others.
Labels:
Bridget Robb,
cardiac lead,
FDA,
Medtronic,
Preemption,
Sprint Fidelis
Thursday, February 7, 2008
Riegel v. Medtronic -- Have You Lost the Right to Sue?
We represent multiple clients who have experienced unnecessary shocking due to Medtronic's faulty lead. One client, in particular, was shocked over thirty times.
What is more frightening is the fact that the Supreme Court recently held oral argument on whether federally approved medical devices are broadly shielded from product-liability lawsuits. If the Supreme Court agrees with this big business position, many people who are injured due to faulty medical devices will be left with no recourse. It seems that big business has bought the FDA since it recently admitted that it cannot keep up with advances in science! The report, from a subcommittee of the FDA's outside Science Board that included members and advisers from industry as well as academia, said the agency "cannot even keep up with the advances in science." An appendix to the report said the FDA conducted twice as many inspections of food facilities in 1973 as it did of all facilities -- including food, drugs and medical devices -- in 2006.
In Riegel v. Medtronic. The Riegel case was brought by a New York man, Charles Riegel, who was injured when a Medtronic catheter burst during a 1996 angioplasty procedure. Riegel, who died in 2004, asserted the catheter had design flaws and that labeling instructions for the device were misleading.
Allison Zieve, a Washington-based attorney representing Riegel, labored to convince the justices that federal law allowed Riegel to sue Medtronic over the device, which had received so-called premarket approval from the Food and Drug Administration.
"It is clear that Congress didn't want any additional requirements", Justice Antonin Scalia said, indicating he thinks Congress wanted the FDA to regulate medical devices without interference from state regulators or courts.
A majority of the Supreme Court appeared to support this view.
The BIGGER QUESTIONS - if the FDA has admitted that it can't protect the people and companies can avoid liability by having its products FDA-approved, what protections are afforded to the users of these products? What incentives do medical device companies have to protect the end user?
February 7, 2008 12:25 PM
What is more frightening is the fact that the Supreme Court recently held oral argument on whether federally approved medical devices are broadly shielded from product-liability lawsuits. If the Supreme Court agrees with this big business position, many people who are injured due to faulty medical devices will be left with no recourse. It seems that big business has bought the FDA since it recently admitted that it cannot keep up with advances in science! The report, from a subcommittee of the FDA's outside Science Board that included members and advisers from industry as well as academia, said the agency "cannot even keep up with the advances in science." An appendix to the report said the FDA conducted twice as many inspections of food facilities in 1973 as it did of all facilities -- including food, drugs and medical devices -- in 2006.
In Riegel v. Medtronic. The Riegel case was brought by a New York man, Charles Riegel, who was injured when a Medtronic catheter burst during a 1996 angioplasty procedure. Riegel, who died in 2004, asserted the catheter had design flaws and that labeling instructions for the device were misleading.
Allison Zieve, a Washington-based attorney representing Riegel, labored to convince the justices that federal law allowed Riegel to sue Medtronic over the device, which had received so-called premarket approval from the Food and Drug Administration.
"It is clear that Congress didn't want any additional requirements", Justice Antonin Scalia said, indicating he thinks Congress wanted the FDA to regulate medical devices without interference from state regulators or courts.
A majority of the Supreme Court appeared to support this view.
The BIGGER QUESTIONS - if the FDA has admitted that it can't protect the people and companies can avoid liability by having its products FDA-approved, what protections are afforded to the users of these products? What incentives do medical device companies have to protect the end user?
February 7, 2008 12:25 PM
Labels:
medical devices,
Medtronic,
Preemption,
Riegel
Monday, December 3, 2007
Recall of Medtronic Sprint Fidelis Lead Wires Exceed 250,000 Worldwide

On October 15, 2007, Medtronic issued a recall of its Sprint Fidelis defibrillator leads as a result of at least five patient deaths in which a lead fracture may have been a contributing cause. Sprint Fidelis Leads are certain models of cardiac electrodes (thin wires) that connect an implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D) directly to the heart. The recalled leads have been implanted in over 200,000 patients since 2004. Most patients with Medtronic defibrillators since 2004, and most patients who received Medtronic defibrillators since then have these leads. A small number of Sprint Fidelis leads are also used with defibrillators made by manufacturers other than Medtronic.
Medtronic estimates a 2.3 percent failure rate in patients with the Sprint Fidelis lead, or 4000 to 5000 people, will experience a lead fracture within 30 months of the device implantation. Replacement of the lead is a serious and delicate procedure which is far more dangerous than replacing the device itself because the lead wires are thread into the interior chamber of the heart.
Generally, patients with heart devices are issued device identification cards that will contain information about their heart device and leads. Patients can check this wallet card for the model number to see if their leads are under recall. The recalled leads are Sprint Fidelis Lead Model Nos. 6930, 6931, 6948 and 6949. These numbers may be shown at the beginning of a longer set of numbers on a patient's identification card.
Complaints against the company allege that a design defect is responsible for the lead fractures. The complaints also allege that Medtronic failed to act timely in recalling the lead as it has known of a large number of failures of the device since at least the end of 2006.
If you would like additional information regarding the aforementioned recall, or would like to speak to an attorney regarding bringing a potential case against Medtronic associated with the implantation of a Sprint Fidelis lead, please contact me directly.
Claudine Q. Homolash has successfully represented hundreds of patients across America who received faulty or recalled medical devices, including implantable cardiac defibrillators and pacemakers.
Labels:
defibrillator,
heart device,
Medtronic,
Sprint Fidelis
Subscribe to:
Posts (Atom)